{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:57:21Z","timestamp":1791579441882,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01HX002422"],"award-info":[{"award-number":["I01HX002422"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.amjmed.2025.05.024","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T18:30:47Z","timestamp":1748111447000},"page":"1528-1538.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Higher Risk of Kidney Failure Associated With Angiotensin Receptor Blockers vs ACE Inhibitors in Patients With Heart Failure"],"prefix":"10.1016","volume":"138","author":[{"given":"Hans J.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiya A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Faselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Palant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh K.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Rangaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose D.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Sheriff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zeng-Treitler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.amjmed.2025.05.024_bib0001","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2025.05.024_bib0002","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2025.05.024_bib0003","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2025.05.024_bib0004","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2025.05.024_bib0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"issue":"9386","key":"10.1016\/j.amjmed.2025.05.024_bib0006","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.amjmed.2025.05.024_bib0007","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2025.05.024_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2025.04.038","article-title":"Renin angiotensin inhibition and lower risk of kidney failure in patients with heart failure","author":"Patel","year":"2025","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2025.05.024_bib0009","article-title":"Lower risk of death and kidney failure associated with higher target (vs. below-target) doses of RAS inhibitors in octogenarians with HFrEF","author":"Sin","year":"2024","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2025.05.024_bib0010","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1002\/ehf2.14787","article-title":"Artificial intelligence approaches for phenotyping heart failure in U.S. Veterans Health Administration electronic health record","volume":"11","author":"Shao","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10.1016\/j.amjmed.2025.05.024_bib0011","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2025.05.024_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132137","article-title":"Temporal trend of first-line drug choice and treatment continuity for hypertension among citizens 75 years or over - a register-based, cohort study","volume":"408","author":"Nielsen","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjmed.2025.05.024_bib0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.amjmed.2025.05.024_bib0014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity score to help design observational studies: Application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Services and Outcomes Research Methodology"},{"issue":"12","key":"10.1016\/j.amjmed.2025.05.024_bib0015","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/pds.968","article-title":"On principles for modeling propensity scores in medical research","volume":"13","author":"Rubin","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.amjmed.2025.05.024_bib0016","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"16","key":"10.1016\/j.amjmed.2025.05.024_bib0017","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.amjmed.2025.05.024_bib0018","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.amjmed.2025.05.024_bib0019","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.amjmed.2023.03.017","article-title":"Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease","volume":"136","author":"Patel","year":"2023","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2025.05.024_bib0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2019.05.064","article-title":"Digoxin discontinuation and outcomes in patients with heart failure with reduced ejection fraction","volume":"74","author":"Malik","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2025.05.024_bib0021","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacc.2020.06.022","article-title":"Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure","volume":"76","author":"Faselis","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.amjmed.2025.05.024_bib0022","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.amjmed.2025.05.024_bib0023","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the Analysis of Survival Data in the Presence of Competing Risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.amjmed.2025.05.024_bib0024","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.amjmed.2025.05.024_bib0025","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00198-019-05048-w","article-title":"Assessing risk factors of non-fatal outcomes amid a competing risk of mortality: the example of hip fracture","volume":"30","author":"Buzkova","year":"2019","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.amjmed.2025.05.024_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255313","article-title":"Competing risk of mortality in association studies of non-fatal events","volume":"16","author":"Buzkova","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2025.05.024_bib0027","series-title":"Observational Studies","first-page":"105","article-title":"Sensitivity to hidden bias","author":"Rosenbaum","year":"2002"},{"issue":"23","key":"10.1016\/j.amjmed.2025.05.024_bib0028","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"9704","key":"10.1016\/j.amjmed.2025.05.024_bib0029","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.amjmed.2025.05.024_bib0030","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjmed.2025.05.024_bib0031","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"9638","key":"10.1016\/j.amjmed.2025.05.024_bib0032","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"9335","key":"10.1016\/j.amjmed.2025.05.024_bib0033","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.amjmed.2025.05.024_bib0034","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.amjmed.2025.05.024_bib0035","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM199810293391804","article-title":"Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects","volume":"339","author":"Gainer","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.amjmed.2025.05.024_bib0036","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2337\/diacare.46.10.1612","article-title":"Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies","volume":"46","author":"Allen","year":"1997","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.amjmed.2025.05.024_bib0037","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","article-title":"Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists","volume":"57","author":"Taal","year":"2000","journal-title":"Kidney Int"},{"issue":"12 Pt 3","key":"10.1016\/j.amjmed.2025.05.024_bib0038","doi-asserted-by":"crossref","first-page":"195S","DOI":"10.1016\/S0895-7061(99)00104-1","article-title":"Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency?","volume":"12","author":"Weir","year":"1999","journal-title":"Am J Hypertens"},{"issue":"4","key":"10.1016\/j.amjmed.2025.05.024_bib0039","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2169\/internalmedicine.45.1515","article-title":"A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy","volume":"45","author":"Shoda","year":"2006","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.amjmed.2025.05.024_bib0040","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE Inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.amjmed.2025.05.024_bib0041","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12933-016-0365-x","article-title":"A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan","volume":"15","author":"Wu","year":"2016","journal-title":"Cardiovasc Diabetol"},{"issue":"9215","key":"10.1016\/j.amjmed.2025.05.024_bib0042","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2013the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.amjmed.2025.05.024_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2024.07.020","article-title":"Angiotensin receptor blockers versus angiotensin converting enzyme inhibitors in acute myocardial infarction without heart failure","volume":"137","author":"Kim","year":"2024","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2025.05.024_bib0044","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"9454","key":"10.1016\/j.amjmed.2025.05.024_bib0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","article-title":"Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.amjmed.2025.05.024_bib0046","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.amjmed.2025.05.024_bib0047","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S2213-8587(23)00291-7","article-title":"Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial","volume":"11","author":"Ahmed","year":"2023","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325003146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325003146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:31:18Z","timestamp":1762079478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934325003146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0002934325003146"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.05.024","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher Risk of Kidney Failure Associated With Angiotensin Receptor Blockers vs ACE Inhibitors in Patients With Heart Failure","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}